Navigation Links
ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
Date:9/6/2007

LEUVEN, Belgium and LUND, Sweden, September 7 /PRNewswire/ --

- Decision Taken to Advance Novel, Long-Acting Anticoagulant Into Phase II Clinical Development

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, and co-development partner, BioInvent International (Nordic Exchange: BINV), announce today that they have successfully completed enrollment and initial follow-up of all volunteers in the first Phase I trial of TB-402, which is being developed for the prevention of venous thromboembolic disorders (VTE - blood clots).

TB-402 is a recombinant human monoclonal antibody that targets factor VIII, a component of the coagulation cascade. This antibody is a promising novel anticoagulant agent particularly because it only partially inhibits factor VIII activity even when administrated in very high doses. This may potentially decrease the risk of undesirable bleedings and the need for monitoring, which are the main concerns associated with anticoagulants currently on the market.

The trial, performed in Denmark, was a randomized, single-dose, placebo-controlled, dose-escalation trial in healthy male volunteers. 56 volunteers were enrolled into the trial, including both younger age volunteers (18-45) and older age volunteers (55-76).

Preliminary results of the trial showed that TB-402 met both the primary (safety and tolerability) and secondary (pharmacokinetic and pharmacodynamic) endpoints. The drug was well tolerated and the study showed that TB-402's prolonged half-life will allow for single-dose treatment in orthopaedic surgery patients and/or once-a-month administration for long-term stroke prevention in atrial fibrillation (AF), as opposed to daily treatment with current anticoagulants. Importantly, the findings confirm that TB-402 achieves only partial inhibition of factor VIII activity without the undesired effect of total factor VIII inactivation. Final data analysis of the first Ph
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle, WARF announce partnership to lure stem cell companies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... York, NY (PRWEB) June 18, 2013 ... innovation and sustainability, the Consulate General of Switzerland in ... solar boat, Switzerland’s MS Tûranor PlanetSolar , to ... part of its DeepWater Expedition 2013 tour with scientists ... led by Capitain Gérard d’Aboville, runs exclusively on energy ...
(Date:6/18/2013)... 2013 DuPont welcomes 48 of the ... DuPont National AgriScience Teachers Ambassador Academy this week (NATAA) ... Md. , The NATAA “Ag Academy” is ... a special project of the National FFA Foundation ... (NAAE) . The highly recommended agriscience teachers, who ...
(Date:6/18/2013)... June 18, 2013 ... research firm, announces the initiation of full ... biopharmaceutical company developing and marketing products for ...      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) ... examining the investment merits of BioAlliance Pharma, ...
(Date:6/18/2013)... This webinar will examine the ... promotion, and review the basic FDA regulations and ... apply these principles through real world case studies ... fundamentals on FDA regulations and guidance related to ...     Assessing traditional and newer forms of promotional materials ...
Breaking Biology Technology:Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 2Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 4DuPont Sponsors National AgriScience Ambassador Academy 2DuPont Sponsors National AgriScience Ambassador Academy 3Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2
... Sept. 18 /PRNewswire-FirstCall/-- Biodel Inc. (Nasdaq:,BIOD) today ... program,at the 43rd Scientific Sessions of the ... VIAject(TM) Phase II meal study data ... entitled, "Pharmacokinetics and pharmacodynamics of,insulin VIAject(TM), insulin ...
... Advantage of ... after HIV Infection, RICHMOND, Calif., Sept. 18 /PRNewswire-FirstCall/ ... the presentation of data,demonstrating that human CD4 T-cells can ... zinc finger DNA-binding protein nucleases,(ZFN(TM)) and preferentially survive and ...
... the Increasing Global Need for Genzyme Products, CAMBRIDGE, ... today broke ground on a significant expansion of its,flagship ... project is focused on adding space for manufacturing support,functions, ... The expansion was marked by a ceremony featuring ...
Cached Biology Technology:Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 2Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 3Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 2Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 3Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 4Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 5Genzyme Begins Major Expansion of Boston Manufacturing Facility 2Genzyme Begins Major Expansion of Boston Manufacturing Facility 3Genzyme Begins Major Expansion of Boston Manufacturing Facility 4Genzyme Begins Major Expansion of Boston Manufacturing Facility 5
(Date:6/18/2013)... of DNA and this modification can occur in ... now, scientists believed that this epigenetic phenomenon actively ... team of researchers from the University of Geneva ... at the Faculty of Medicine, reveals that this ... methylation may play both a passive and active ...
(Date:6/18/2013)... of Adelaide shows that weight gain and increased head size ... a higher IQ at early school age. , The study was ... from more than 13,800 children who were born full-term. , The ... that babies who put on 40% of their birthweight in the ... time they were six years of age, compared with babies who ...
(Date:6/17/2013)... with central nervous system infections may well be suffering ... to a study to be published in mBio ... for Microbiology. Researchers have detected the virus in spinal ... nervous system infections of unknown cause, and in an ... and poultry, suggesting animals may serve as reservoirs for ...
Breaking Biology News(10 mins):The secret of DNA methylation 2IQ link to baby's weight gain in first month 2New virus discovered in patients with central nervous system infections 2New virus discovered in patients with central nervous system infections 3
... more than 10 years of cooperative research on ... the USDA Forest Service,s Pacific Southwest Research Station ... Phytophthora ramorum : A Summary of the Literature." ... of topics, including a history of sudden oak ...
... Vegas, NV (Dec. 24, 2010) - Three weeks of ... heart attack returned microRNA activity close to their pre-event ... studied, just six were attributed to exerting the majority ... study four microRNA optimally regulated by Longevinex and ...
... An expert working group of the International ... Clinical Chemistry and Laboratory Medicine (IFCC) has released ... of bone turnover markers (BTMs) in fracture risk ... it identifies research priorities and recommends that specific ...
Cached Biology News:Comprehensive report on sudden oak death 2Longevinex exerts greater influence over genes than resveratrol 2Longevinex exerts greater influence over genes than resveratrol 3Standardized protocols would greatly enhance clinical and research potential of BTMs 2
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human CD69 TAC is designed to deplete human CD69 from samples to isolate resting CD4+ or CD8+ T cells....
This bispecific antibody complex has been tested for efficient depletion of CD41+ cells using the StemSep ; negative immunomagnetic cell separation system....
... is a modular confocal system that gives ... ultra-compact and lightweight design. The improved scan ... performance to 400nm andits bi-directional scanner provides ... X and Y scan axes rotation and ...
... COOLSCOPE is an integrated digital microscope ... a computer, equipment setup, optical adjustment or ... and innovative technology, COOLSCOPE combines simplicity and ... The COOLSCOPE offers simultaneous viewing of a ...
Biology Products: